300 results
Page 3 of 15
8-K
EX-99.2
7eyfxwpn
8 Sep 21
Regulation FD Disclosure
4:00pm
8-K
EX-99.1
4dequqg
25 Aug 21
Other Events
1:23pm
8-K
EX-99.1
10tnpevm
5 Aug 21
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
4:01pm
8-K
EX-99.1
eggw2gqm fwsohuozljz
12 Jul 21
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
11:13am
8-K
EX-99.1
7aa1g
10 Jun 21
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
4:07pm
8-K
EX-99.1
rpn zxwzdzq3
8 Jun 21
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
8:41am
8-K
EX-99.1
w9e99yipm4t8co4gckjf
1 Jun 21
Regulation FD Disclosure
10:52am
8-K
EX-99.1
ti4gtl7aa8o
6 May 21
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
4:01pm
8-K
EX-99.2
yihz199w6qk
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.1
afzhnj jz
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.3
q68z6q
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.4
mq0md4urgremu3b99
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
S-3ASR
EX-1.2
hr7kdbg1na sy5z
12 Mar 21
Automatic shelf registration
4:10pm
8-K
EX-99.1
sk5r1qsyima2nt8kl
25 Feb 21
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
4:02pm
8-K
EX-99.1
2sxakxnsm79exdqxgi1
11 Feb 21
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule
10:39am
8-K
EX-99.1
in48 41ezvzq
26 Jan 21
Other Events
11:19am
8-K
EX-99.1
je09vz
15 Jan 21
Other Events
11:34am